EW · 10-Q · 2026Q3 · Full report
Capital Return Program
Edwards Lifesciences Corp · 2026-11-04 · Importance 58 · Surprise 42 · Matches filing data
During the nine months ended September 30, 2026, Edwards repurchased 8.5 million shares for $696.6 million under its Board-authorized program. The purchases included a $500.0 million accelerated share repurchase agreement executed during the period. At September 30, 2026, approximately $1.3 billion remained authorized for repurchases. Financing cash flows included $714.0 million of treasury-stock purchases during the nine-month period.
Key facts
- At September 30, 2026, Edwards Lifesciences had approximately $1.3 billion of remaining share repurchase authorization. source
- Edwards Lifesciences repurchased 8.5 million shares for $696.6 million during the first nine months of 2026, including under a $500.0 million accelerated share repurchase agreement. source
- Edwards Lifesciences used $552.3 million in financing activities in the nine months ended September 30, 2026, primarily for $714.0 million of treasury stock purchases, partly offset by $159.2 million of stock-plan proceeds. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -3.9% | At September 30, 2026, Edwards Lifesciences had approximately $1.3 billion of remaining share repurchase authorization. |
| cash | negative | realized | -3.9% | Edwards Lifesciences used $552.3 million in financing activities in the nine months ended September 30, 2026, primarily for $714.0 million… |